[{"orgOrder":0,"company":"Fate Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||CD16","graph1":"Oncology","graph2":"Phase I","graph3":"Fate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Fate Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Fate Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Fate Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"FT516","moa":"CD20","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Fate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fate Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Fate Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Fate Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"FT825","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Fate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fate Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Fate Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Fate Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"FT819","moa":"CAR19 T-cell","graph1":"Oncology","graph2":"IND Enabling","graph3":"Fate Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fate Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Fate Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Fate Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"FT538","moa":"CD16","graph1":"Oncology","graph2":"Preclinical","graph3":"Fate Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fate Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Fate Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Fate Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"FT819","moa":"||CAR19 T-cell","graph1":"Immunology","graph2":"Phase I","graph3":"Fate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Fate Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Fate Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Fate Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"FT516","moa":"||CD20","graph1":"Oncology","graph2":"Phase I","graph3":"Fate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Fate Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Fate Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Fate Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"FT516","moa":"||CD20","graph1":"Oncology","graph2":"Phase I","graph3":"Fate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Fate Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Fate Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Fate Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"FT819","moa":"||CAR19 T-cell","graph1":"Oncology","graph2":"Phase I","graph3":"Fate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fate Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Fate Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Fate Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"FT819","moa":"CAR19 T-cell","graph1":"Oncology","graph2":"Phase I","graph3":"Fate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fate Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Fate Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Fate Therapeutics","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Public Offering","leadProduct":"FT576","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Fate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Fate Therapeutics \/ BofA Securities","highestDevelopmentStatusID":"6","companyTruncated":"Fate Therapeutics \/ BofA Securities"},{"orgOrder":0,"company":"Fate Therapeutics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Termination","leadProduct":"Cyclophosphamide","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Fate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Fate Therapeutics \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"6","companyTruncated":"Fate Therapeutics \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Fate Therapeutics","sponsor":"Janssen Biotech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Fate Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Fate Therapeutics \/ Janssen Biotech","highestDevelopmentStatusID":"4","companyTruncated":"Fate Therapeutics \/ Janssen Biotech"},{"orgOrder":0,"company":"Fate Therapeutics","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"||Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Fate Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Fate Therapeutics \/ Ono Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"Fate Therapeutics \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Fate Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"FT536","moa":"CD16","graph1":"Oncology","graph2":"Preclinical","graph3":"Fate Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fate Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Fate Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Fate Therapeutics","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"ONO-8250","moa":"HER2","graph1":"Oncology","graph2":"Preclinical","graph3":"Fate Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fate Therapeutics \/ Ono Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"Fate Therapeutics \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Fate Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Fate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Fate Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Fate Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Fate Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"FT819","moa":"CD19","graph1":"Immunology","graph2":"Phase I","graph3":"Fate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Fate Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Fate Therapeutics \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals by Fate Therapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Iran Expo
                          Not Confirmed
                          Iran Expo
                          Not Confirmed

                          Details : FT819 is the first-ever, off-the-shelf, iPSC-derived CAR T-cell therapy, which is currently being evaluated for the treatment of moderate to severe active systemic lupus erythematosus.

                          Product Name : FT819

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Inapplicable

                          April 14, 2025

                          Lead Product(s) : FT819

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Iran Expo
                          Not Confirmed
                          Iran Expo
                          Not Confirmed

                          Details : FT819 is the first-ever, off-the-shelf, iPSC-derived CAR T-cell therapy, which is currently being evaluated for the treatment of moderate to severe active systemic lupus erythematosus.

                          Product Name : FT819

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Inapplicable

                          September 05, 2024

                          Lead Product(s) : FT819,Cyclophosphamide,Fludarabine Phosphate

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Iran Expo
                          Not Confirmed
                          Iran Expo
                          Not Confirmed

                          Details : ONO-8250 (FT825) is a multiplexed-engineered CAR T-cell candidate targeting HER2, under Phase 1 trials for HER2-expressing advanced solid tumors.

                          Product Name : ONO-8250

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Inapplicable

                          August 01, 2024

                          Lead Product(s) : FT825

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Iran Expo
                          Not Confirmed
                          Iran Expo
                          Not Confirmed

                          Details : The Company plans to use net proceeds to fund clinical trials and nonclinical studies of its candidates, including FT576, an investigational CAR NK cell cancer immunotherapy.

                          Product Name : FT576

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          March 19, 2024

                          Lead Product(s) : FT576

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : BofA Securities

                          Deal Size : $100.0 million

                          Deal Type : Public Offering

                          blank

                          05

                          Iran Expo
                          Not Confirmed
                          Iran Expo
                          Not Confirmed

                          Details : FT522 is an iPSC-derived CAR NK cell targeting CD19 with ADR technology, under evaluation for relapsed/refractory B-cell lymphoma.

                          Product Name : FT522

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Inapplicable

                          March 05, 2024

                          Lead Product(s) : FT522,Cyclophosphamide,Rituximab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Iran Expo
                          Not Confirmed
                          Iran Expo
                          Not Confirmed

                          Details : FT576 (CAR NK cells) is an investigational, universal, off-the-shelf NK cell cancer immunotherapy derived from a clonal master iPSC line. FT576 incorporates a proprietary CAR that targets BCMA, a novel high-affinity 158V and non-cleavable CD16 (hnCD16) F...

                          Product Name : FT576

                          Product Type : Cell and Gene therapy

                          Upfront Cash : $100.0 million

                          May 01, 2023

                          Lead Product(s) : FT576,Cyclophosphamide,Fludarabine Phosphate

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Johnson & Johnson Innovative Medicine

                          Deal Size : $3,100.0 million

                          Deal Type : Termination

                          blank

                          07

                          Iran Expo
                          Not Confirmed
                          Iran Expo
                          Not Confirmed

                          Details : FT819 is an investigational, universal, off-the-shelf, T-cell receptor (TCR)-less CD19 chimeric antigen receptor (CAR) T-cell cancer immunotherapy derived from a clonal master induced pluripotent stem cell (iPSC) line.

                          Product Name : FT819

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Inapplicable

                          October 12, 2022

                          Lead Product(s) : FT819,Cyclophosphamide,Fludarabine Phosphate

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          Iran Expo
                          Not Confirmed
                          Iran Expo
                          Not Confirmed

                          Details : FT536 also incorporates a novel high-affinity 158V, non-cleavable CD16 (hnCD16) Fc receptor, which has been modified to prevent its down-regulation and to enhance its binding to tumor-targeting antibodies; an IL-15 receptor fusion (IL-15RF) that augments...

                          Product Name : FT536

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Inapplicable

                          October 01, 2022

                          Lead Product(s) : FT536

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          Iran Expo
                          Not Confirmed
                          Iran Expo
                          Not Confirmed

                          Details : Under the terms of the Collaboration and Option Agreement, the parties will jointly develop and commercialize FT825 (ONO-8250) in the U.S. and Europe, and ONO maintains exclusive development and commercialization rights for FT825 (ONO-8250) in the rest o...

                          Product Name : FT825

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          July 11, 2022

                          Lead Product(s) : ONO-8250

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Ono Pharmaceutical

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          10

                          Iran Expo
                          Not Confirmed
                          Iran Expo
                          Not Confirmed

                          Details : With this agreement, the discovery of iPSC-derived CAR-NK cell therapy will be added to iPSC-derived CAR-T cells therapy for solid tumors. And, a second new target for solid tumor collaboration has been added and ONO will provide Fate with antibodies tha...

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          June 28, 2022

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Ono Pharmaceutical

                          Deal Size : Undisclosed

                          Deal Type : Expanded Collaboration

                          blank